Compare ENOV & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENOV | EYPT |
|---|---|---|
| Founded | 1995 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Fluid Controls | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2008 | 2005 |
| Metric | ENOV | EYPT |
|---|---|---|
| Price | $27.24 | $17.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 5 |
| Target Price | ★ $49.14 | $29.60 |
| AVG Volume (30 Days) | 854.1K | ★ 1.1M |
| Earning Date | 11-06-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,233,266,000.00 | $42,339,000.00 |
| Revenue This Year | $9.27 | N/A |
| Revenue Next Year | $4.56 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 11.57 | N/A |
| 52 Week Low | $25.47 | $3.91 |
| 52 Week High | $49.38 | $19.11 |
| Indicator | ENOV | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 43.46 | 63.77 |
| Support Level | $25.52 | $15.81 |
| Resistance Level | $28.02 | $17.40 |
| Average True Range (ATR) | 1.28 | 1.02 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 31.79 | 62.18 |
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.